Related Experiment Video
Updated: Jun 3, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Targeting eosinophil biology in asthma therapy
1Experimental Pneumology, Research Center Borstel, Parkallee 1, D-23845 Borstel, Germany 1887402. mwegmann@fz-borstel.de
Summary
Eosinophils are key in fighting parasites but their role in asthma is debated. New research questions their direct involvement in airway destruction, impacting asthma therapy targets.
Area of Science:
- Immunology
- Allergy Research
- Pulmonology
Background:
- Eosinophils are crucial immune cells for combating parasitic infections.
- Their precise role in allergic diseases like asthma remains controversial.
- Historically, eosinophils were implicated in airway tissue damage in asthma.
Purpose of the Study:
- To critically review the role of eosinophils in asthma pathogenesis.
- To summarize therapeutic strategies targeting eosinophils in asthma.
- To evaluate recent findings questioning the eosinophil's direct role in asthma.
Main Methods:
- Review of scientific literature on eosinophil function in asthma.
- Analysis of in vitro and animal models of experimental asthma.
- Evaluation of clinical trial data for eosinophil-targeted therapies.
Main Results:
- Numerous mediators and receptors regulating eosinophil activity have been identified.
- Therapeutic interventions targeting these molecules have yielded surprising results in clinical studies.
- Current evidence challenges the established view of eosinophils as primary drivers of asthma pathology.
Conclusions:
- The direct role of eosinophils in causing airway destruction in asthma is increasingly questioned.
- Further research is needed to clarify eosinophil involvement and refine targeted therapies.
- Eosinophil-specific asthma treatments require re-evaluation based on emerging data.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: